The GErman Italian Spanish Takotsubo (GEIST) Registry
Launched by PROF. DR. MED. INGO EITEL · Apr 22, 2020
Trial Information
Current as of November 13, 2025
Recruiting
Keywords
ClinConnect Summary
The GEIST Registry is a medical study that aims to learn more about Takotsubo syndrome, a condition that can cause sudden heart muscle weakness and is often triggered by stress. This international study is collecting information from patients diagnosed with Takotsubo syndrome across multiple centers. Researchers want to gather details about patients' backgrounds, symptoms, lab tests, heart imaging results, treatments, and how they recover both in the hospital and afterward. By doing this, they hope to better understand the disease and improve care for future patients.
If you or someone you know has been diagnosed with Takotsubo syndrome, you may be eligible to participate in this study. The trial is open to individuals aged 65 and older, regardless of gender. Participants will provide information about their health and experiences related to the condition, which will help researchers gain valuable insights. This is a great opportunity to contribute to medical knowledge that could benefit many others facing this syndrome.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with Takotsubo syndrome
- Exclusion Criteria:
- • Non
About Prof. Dr. Med. Ingo Eitel
Prof. Dr. Med. Ingo Eitel is a distinguished clinical trial sponsor with extensive expertise in medical research and innovative therapeutic development. With a strong focus on advancing patient care through rigorous scientific investigation, he leads initiatives that encompass a wide range of therapeutic areas. His commitment to excellence in clinical trials is underscored by a collaborative approach, fostering partnerships with leading research institutions and healthcare professionals. Prof. Eitel's leadership is characterized by a dedication to ethical standards, patient safety, and the pursuit of groundbreaking medical solutions that aim to improve health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Foggia, Italy
Lübeck, Schleswig Holstein, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials